19 Dec 2022 FOx BIOSYSTEMS receives € 2.5 million EIC grant to accelerate the market introduction of unique EV analysis and isolation application Member news
16 Dec 2022 Oxurion announces the continuation of KALAHARI Phase 2, Part B Study in diabetic macular edema following interim analysis Member news
09 Dec 2022 UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa Member news
21 Nov 2022 Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023 Member news
17 Nov 2022 BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma Member news
15 Nov 2022 Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia Member news
15 Nov 2022 Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON Member news
04 Nov 2022 Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results Member news
25 Oct 2022 Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON) Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
